Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Ref Type
Authors E. Lew, C. Walsh, E. Martin, A. Albert, G.G. Li, Y. Yokoyama
Title Immuno-oncologic efficacy of RXDX-106, a selective, TAM family small molecule kinase inhibitor
Abstract Text European Journal of Cancer, Vol 69, Supplement 1, December 2016, Page S31


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
RXDX-106 RXDX-106 0 0
Drug Name Trade Name Synonyms Drug Classes Drug Description
RXDX-106 CEP-40783|CEP40783|CEP 40783|RXDX106|RXDX 106 AXL Inhibitor 29 MERTK Inhibitor 13 MET Inhibitor 58 TYRO3 Inhibitor 8 RXDX-106 (CEP-40783) is a small molecule inhibitor of TAM family kinases (Axl, Mertk, and Tyro3) and Met that promotes anti-tumor immune response, resulting in tumor growth inhibition (Eur J Cancer, Vol 69, Supplement 1, December 2016, Page S31, PMID: 30501104, PMID: 30723115).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References